Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2018

01-04-2018 | Original Article

Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria

Authors: Eiichiro Yasutomi, Namiko Hoshi, Soichiro Adachi, Takafumi Otsuka, Lingling Kong, Yuna Ku, Haruka Yamairi, Jun Inoue, Tsukasa Ishida, Daisuke Watanabe, Makoto Ooi, Masaru Yoshida, Tomoya Tsukimi, Shinji Fukuda, Takeshi Azuma

Published in: Digestive Diseases and Sciences | Issue 4/2018

Login to get access

Abstract

Background and Aims

Proton pump inhibitors (PPIs) are among the most frequently prescribed medications. Side effects including an increased risk of intestinal infections have been reported. It is assumed that PPIs can increase susceptibility to enteropathogens; however, the underlying mechanisms are unknown. Here in this study, we explored whether Lansoprazole (Laz), one of the PPIs, increases the susceptibility to enteropathogens, and further investigated the mechanism of it.

Methods

Mice were administered Laz intraperitoneally once daily and orally infected with Citrobacter rodentium (C. rodentium). The establishment of intestinal infection was assessed by histology and inflammatory cytokine expression levels measured by quantitative PCR. To test whether Laz changes the intestinal environment to influence the susceptibility, intestinal pH, microbiota, metabolites and immune cell distributions were evaluated via pH measurement, 16S rRNA gene sequencing, metabolome, and flow cytometry analyses after Laz administration.

Results

Colitis was induced with less C. rodentium in Laz-treated mice as compared with the controls. We found that increased numbers of C. rodentium could reach the cecum following Laz administration. Laz increased pH in the stomach but not in the intestines. It induced dysbiosis and changed the metabolite content of the small intestine. However, these changes did not lead to alterations of immune cell distribution.

Conclusions

Laz raised susceptibility to C. rodentium as increased numbers of the pathogen reach the site of infection. Our results suggest that it was due to increased stomach pH which allowed more peroral enteropathogens to pass the stomach, but not because of changes of intestinal environment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2:132–139.CrossRefPubMed Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2:132–139.CrossRefPubMed
2.
go back to reference Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32:258–264.CrossRefPubMed Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32:258–264.CrossRefPubMed
3.
go back to reference Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Int Med. 2016;176:238–246.CrossRef Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Int Med. 2016;176:238–246.CrossRef
4.
go back to reference Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112:1084–1093.CrossRefPubMed Wang YF, Chen YT, Luo JC, Chen TJ, Wu JC, Wang SJ. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112:1084–1093.CrossRefPubMed
5.
go back to reference Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172–174.CrossRefPubMed Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176:172–174.CrossRefPubMed
6.
go back to reference Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed
7.
8.
go back to reference Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol.. 2012;107:1011–1019.CrossRefPubMed Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol.. 2012;107:1011–1019.CrossRefPubMed
9.
go back to reference Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59:1554–1558.CrossRefPubMedPubMedCentral Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59:1554–1558.CrossRefPubMedPubMedCentral
10.
go back to reference Wei L, Ratnayake L, Phillips G, et al. Acid suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol. 2017;83:1298–1308.CrossRefPubMedPubMedCentral Wei L, Ratnayake L, Phillips G, et al. Acid suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol. 2017;83:1298–1308.CrossRefPubMedPubMedCentral
11.
go back to reference Riedl RA, Atkinson SN, Burnett CML, Grobe JL, Kirby JR. The gut microbiome, energy homeostasis, and implications for hypertension. Curr Hypertens Rep. 2017;19:27.CrossRefPubMed Riedl RA, Atkinson SN, Burnett CML, Grobe JL, Kirby JR. The gut microbiome, energy homeostasis, and implications for hypertension. Curr Hypertens Rep. 2017;19:27.CrossRefPubMed
13.
go back to reference Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature. 2014;514:508–512.CrossRefPubMedPubMedCentral Schulz MD, Atay C, Heringer J, et al. High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. Nature. 2014;514:508–512.CrossRefPubMedPubMedCentral
14.
go back to reference Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–13785.CrossRefPubMedPubMedCentral Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–13785.CrossRefPubMedPubMedCentral
15.
16.
go back to reference Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–241.CrossRefPubMed Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–241.CrossRefPubMed
17.
go back to reference Hoshi N, Schenten D, Nish SA, et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat Commun. 2012;3:1120.CrossRefPubMedPubMedCentral Hoshi N, Schenten D, Nish SA, et al. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat Commun. 2012;3:1120.CrossRefPubMedPubMedCentral
18.
go back to reference Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.CrossRefPubMed Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.CrossRefPubMed
19.
go back to reference Imhann F, Bonder MJ, Vila AV, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748.CrossRefPubMed Imhann F, Bonder MJ, Vila AV, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748.CrossRefPubMed
23.
go back to reference Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31:677–689.CrossRefPubMed Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 2009;31:677–689.CrossRefPubMed
24.
go back to reference Koh A, Vadder FD, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345.CrossRefPubMed Koh A, Vadder FD, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–1345.CrossRefPubMed
25.
go back to reference Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–455.CrossRefPubMedPubMedCentral Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504:451–455.CrossRefPubMedPubMedCentral
26.
go back to reference Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–573.CrossRefPubMed Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–573.CrossRefPubMed
27.
go back to reference Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE. 2015;10:e0124653.CrossRefPubMedPubMedCentral Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS ONE. 2015;10:e0124653.CrossRefPubMedPubMedCentral
28.
go back to reference Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153:378–386.CrossRefPubMed Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153:378–386.CrossRefPubMed
29.
go back to reference Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845–853.CrossRefPubMed Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845–853.CrossRefPubMed
30.
go back to reference Collins JW, Keeney KM, Crepin VF, et al. Citrobacter rodentium; infection, inflammation and the microbiota. Nat Rev Microbiol. 2014;12:612–623.CrossRefPubMed Collins JW, Keeney KM, Crepin VF, et al. Citrobacter rodentium; infection, inflammation and the microbiota. Nat Rev Microbiol. 2014;12:612–623.CrossRefPubMed
31.
go back to reference Eckmann L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann N Y Acad Sci. 2006;1072:28–38.CrossRefPubMed Eckmann L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann N Y Acad Sci. 2006;1072:28–38.CrossRefPubMed
32.
go back to reference Magwedere K, Mukaratirwa S. Evaluation of intestinal pH and osmolality levels in rats (Rattus norvegicus) and chickens (Gallus gallus) experimentally infected with Trichinella zimbabwensis. Int J Appl Res Vet Med. 2008;6:166–174. Magwedere K, Mukaratirwa S. Evaluation of intestinal pH and osmolality levels in rats (Rattus norvegicus) and chickens (Gallus gallus) experimentally infected with Trichinella zimbabwensis. Int J Appl Res Vet Med. 2008;6:166–174.
33.
go back to reference Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–450.CrossRefPubMed Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–450.CrossRefPubMed
34.
35.
go back to reference Mishima E, Fukuda S, Shima H, et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol. 2015;26:1787–1794.CrossRefPubMed Mishima E, Fukuda S, Shima H, et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol. 2015;26:1787–1794.CrossRefPubMed
36.
go back to reference Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78–95.CrossRefPubMed Sugimoto M, Wong DT, Hirayama A, et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78–95.CrossRefPubMed
38.
go back to reference Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4:337–349.CrossRefPubMedPubMedCentral Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4:337–349.CrossRefPubMedPubMedCentral
39.
go back to reference Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232–236.CrossRefPubMed Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232–236.CrossRefPubMed
40.
go back to reference Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–341.CrossRefPubMed Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–341.CrossRefPubMed
41.
go back to reference Jiminez JA, Uwiera TC, Abbott DW, Uwiera RRE, Inglis GD. Butyrate supplementation at high concentrations alters enteric bacterial communities and reduces intestinal inflammation in mice infected with Citrobacter rodentium. mSphere. 2017;2:e00243-17.CrossRefPubMedPubMedCentral Jiminez JA, Uwiera TC, Abbott DW, Uwiera RRE, Inglis GD. Butyrate supplementation at high concentrations alters enteric bacterial communities and reduces intestinal inflammation in mice infected with Citrobacter rodentium. mSphere. 2017;2:e00243-17.CrossRefPubMedPubMedCentral
42.
go back to reference Geddes K, Rubino SJ, Magalhaes JG, et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med. 2011;17:837–844.CrossRefPubMed Geddes K, Rubino SJ, Magalhaes JG, et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med. 2011;17:837–844.CrossRefPubMed
43.
go back to reference Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA Jr, Phillips EJ. Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol. 2017;83:1896–1911.CrossRefPubMed Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA Jr, Phillips EJ. Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol. 2017;83:1896–1911.CrossRefPubMed
44.
go back to reference Hess MW, de Baaij JH, Gommers LM, Hoenderop JG, Bindels RJ. Dietary inulin fibers prevent proton-pump inhibitor (PPI)-induced hypocalcemia in mice. PLoS ONE. 2015;10:e0138881.CrossRefPubMedPubMedCentral Hess MW, de Baaij JH, Gommers LM, Hoenderop JG, Bindels RJ. Dietary inulin fibers prevent proton-pump inhibitor (PPI)-induced hypocalcemia in mice. PLoS ONE. 2015;10:e0138881.CrossRefPubMedPubMedCentral
45.
go back to reference Kim YG, Sakamoto K, Seo SU, et al. Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens. Science. 2017;356:315–319.CrossRefPubMed Kim YG, Sakamoto K, Seo SU, et al. Neonatal acquisition of Clostridia species protects against colonization by bacterial pathogens. Science. 2017;356:315–319.CrossRefPubMed
46.
go back to reference Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76:639–645.CrossRefPubMed Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76:639–645.CrossRefPubMed
47.
go back to reference Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19:12–18.CrossRefPubMed Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Clin Nutr Metab Care. 2016;19:12–18.CrossRefPubMed
48.
go back to reference Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–440.CrossRefPubMed Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–440.CrossRefPubMed
Metadata
Title
Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria
Authors
Eiichiro Yasutomi
Namiko Hoshi
Soichiro Adachi
Takafumi Otsuka
Lingling Kong
Yuna Ku
Haruka Yamairi
Jun Inoue
Tsukasa Ishida
Daisuke Watanabe
Makoto Ooi
Masaru Yoshida
Tomoya Tsukimi
Shinji Fukuda
Takeshi Azuma
Publication date
01-04-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4905-3

Other articles of this Issue 4/2018

Digestive Diseases and Sciences 4/2018 Go to the issue

Profiles and Perspectives

Profiles: Benjamin Lebwohl, MD, MS